Humedix Co., Ltd. (200670.KQ)
KRW 38300.0
(-0.78%)
KRW 38300.0
(-0.78%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -77.54 Billion KRW | -40.83% |
| 2022 | -55.06 Billion KRW | -335.52% |
| 2021 | 23.37 Billion KRW | 407.36% |
| 2020 | -7.6 Billion KRW | 56.22% |
| 2019 | -17.37 Billion KRW | 33.17% |
| 2018 | -25.99 Billion KRW | 7.23% |
| 2017 | -28.02 Billion KRW | 42.99% |
| 2016 | -49.15 Billion KRW | 27.4% |
| 2015 | -67.71 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -87.09 Billion KRW | -12.32% |
| 2024 Q2 | -85.85 Billion KRW | 1.42% |
| 2023 Q3 | -70.04 Billion KRW | -23.91% |
| 2023 FY | -77.54 Billion KRW | -40.83% |
| 2023 Q2 | -56.53 Billion KRW | -17.06% |
| 2023 Q4 | -77.54 Billion KRW | -10.71% |
| 2023 Q1 | -48.29 Billion KRW | 12.3% |
| 2022 FY | -55.06 Billion KRW | -335.52% |
| 2022 Q4 | -55.06 Billion KRW | -332.62% |
| 2022 Q3 | 23.67 Billion KRW | 10.89% |
| 2022 Q2 | 21.34 Billion KRW | 1.42% |
| 2022 Q1 | 21.04 Billion KRW | -9.98% |
| 2021 FY | 23.37 Billion KRW | 407.36% |
| 2021 Q3 | 20.53 Billion KRW | 40.3% |
| 2021 Q4 | 23.37 Billion KRW | 13.85% |
| 2021 Q2 | 14.63 Billion KRW | 198244.24% |
| 2021 Q1 | -7.38 Million KRW | 6.51% |
| 2020 Q3 | 3.27 Million KRW | 9050.78% |
| 2020 FY | -7.6 Billion KRW | 56.22% |
| 2020 Q4 | -7.9 Million KRW | -341.3% |
| 2020 Q1 | -16.19 Million KRW | 8.17% |
| 2020 Q2 | -36.58 Thousand KRW | 99.77% |
| 2019 Q4 | -17.63 Million KRW | -4.87% |
| 2019 FY | -17.37 Billion KRW | 33.17% |
| 2019 Q3 | -16.81 Million KRW | -32.8% |
| 2019 Q2 | -12.66 Million KRW | 43.6% |
| 2019 Q1 | -22.45 Million KRW | 13.63% |
| 2018 Q3 | -22.66 Million KRW | 2.61% |
| 2018 FY | -25.99 Billion KRW | 7.23% |
| 2018 Q1 | -25.12 Million KRW | 10.33% |
| 2018 Q4 | -25.99 Million KRW | -14.73% |
| 2018 Q2 | -23.26 Million KRW | 7.41% |
| 2017 FY | -28.02 Billion KRW | 42.99% |
| 2017 Q4 | -28.02 Million KRW | -2.46% |
| 2017 Q1 | -36.95 Million KRW | 24.83% |
| 2017 Q2 | -29.82 Million KRW | 19.29% |
| 2017 Q3 | -27.35 Million KRW | 8.28% |
| 2016 Q4 | -49.15 Million KRW | 0.0% |
| 2016 FY | -49.15 Billion KRW | 27.4% |
| 2016 Q1 | 67.96 Million KRW | 0.0% |
| 2015 FY | -67.71 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 18.96 Billion KRW | 508.969% |
| CMG Pharmaceutical Co., Ltd. | 18.78 Billion KRW | 512.824% |
| Celltrion Pharm, Inc. | 142.81 Billion KRW | 154.298% |
| Huons Global Co., Ltd. | 13.26 Billion KRW | 684.591% |
| DongKook Pharmaceutical Co., Ltd. | 44.19 Billion KRW | 275.465% |
| Enzychem Lifesciences Corporation | -9.81 Billion KRW | -690.212% |
| Boditech Med Inc. | -31.92 Billion KRW | -142.889% |
| EuBiologics Co., Ltd. | 4.88 Billion KRW | 1688.56% |
| FutureChem Co.,Ltd | -4.93 Billion KRW | -1472.733% |
| Huons Co., Ltd. | 73.9 Billion KRW | 204.919% |
| BNC Korea Co., Ltd. | -67.65 Billion KRW | -14.627% |
| AptaBio Therapeutics Inc. | -12.08 Billion KRW | -541.813% |